Key Points

Eli Lilly continues to report excellent performance, which is expected to persist.
The pharmaceutical firm leads in its primary treatment category.
The company features multiple promising developments in its development pipeline.

Eli Lilly (NYSE: LLY) has outperformed the wider stock market over the last five years, rising to become the biggest healthcare entity - and the initial one valued at $1 trillion.

While some investors think the shares reflect flawless expectations with limited further gains, the drugmaker keeps surprising skeptics. It achieved this once more in its latest earnings report.

Let's examine three factors supporting an investment in the shares.

Image source: Getty Images.

1. Eli Lilly delivers exceptional financial outcomes

The revenue expansion Eli Lilly has achieved stands out remarkably for a major drug company, where annual sales growth in the low double digits typically counts as robust. In the fourth quarter, Lilly repeated this feat: Revenue reached $19.3 billion, rising 43% from the prior year; adjusted earnings per share hit $7.54, climbing 42% versus the same period last year.

Eli Lilly's expansion will moderate notably this year - its forecast for revenue between $80 billion and $83 billion points to top-line growth of 25% at the midpoint. Yet this still exceeded analyst projections and appears robust in context, even after the firm reduced prices on select key products to meet requests from the Trump administration. Eli Lilly should keep generating solid financial results, providing another solid basis for acquiring the stock.

2. Lilly advances in a critical sector

The firm's efforts in diabetes and weight control drive most of the momentum. Its tirzepatide medication, marketed as Mounjaro and Zepbound, produced more than $30 billion in revenue during 2025 and ranks as the top-selling compound globally.

Everyone knows Eli Lilly vies with Novo Nordisk in the diabetes and weight reduction fields, yet Lilly is clearly prevailing. It stated that its portion of the incretin analog market has risen steadily since 2023, hitting 60.5% by the close of 2025. Novo Nordisk's share has declined in the opposite direction, now at just 39.1%. Eli Lilly should maintain its lead in this arena, which represents positive developments.

3. Lilly possesses several compelling pipeline prospects

Another factor ensuring Lilly stays ahead involves its array of attractive candidates that will bolster its already dominant lineup. Its oral GLP-1 agent, orforglipron, could gain clearance by the second quarter of 2026. Its retatrutide compound, which acts on three hormones tied to weight reduction, delivered strong phase 3 data. Additional options follow these.

Eli Lilly shows no indication of easing its pace, whether regarding its pipeline or commercial advancements. The stock may retain considerable potential; it is not too late to invest.

Should you acquire shares in Eli Lilly at present?

Before purchasing shares in Eli Lilly, review this:

The Motley Fool Stock Advisor analyst group recently pinpointed what they view as the 10 strongest stocks for investors to acquire now... and Eli Lilly did not appear among them. The 10 selections that qualified could generate substantial returns over the next several years.

Recall when Netflix appeared on this list on December 17, 2004... an investment of $1,000 at the recommendation time would now equal $443,353!* Or when Nvidia joined on April 15, 2005... a $1,000 investment then would now total $1,155,789!*

Stock Advisor's overall average return stands at 920% - a market-beating result versus 196% for the S&P 500. Do not overlook the newest top 10 roster, accessible via Stock Advisor, and enter an investing group created by individual investors for individual investors.

*Stock Advisor returns as of February 11, 2026.

Prosper Junior Bakiny holds stakes in Eli Lilly and Novo Nordisk. The Motley Fool endorses Novo Nordisk. The Motley Fool maintains a disclosure policy.

The perspectives and statements here represent those of the author and may not align with those of Nasdaq, Inc.